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Purpose:  A  non-randomised,  open-label,  Phase  I  safety  and  immunogenicity  dose-ﬁnding  study  to  assess
the  safety  and  immunogenicity  of the  candidate  TB  vaccine  Modiﬁed  Vaccinia  virus  Ankara  expressing
Antigen  85A  (MVA85A)  from  Mycobacterium  tuberculosis  (MTB)  in  healthy  adult  volunteers  previously
vaccinated  with  BCG.
Methods: Healthy  BCG-vaccinated  volunteers  were  vaccinated  with  either  1  ×  107 or  1  ×  108 PFU  of
MVA85A.  All  adverse  events  were  documented  and  antigen  speciﬁc  T cell  responses  were  measured
using  an  ex  vivo  IFN-  ELISPOT  assay.  Safety  and immunogenicity  were  compared  between  the  2 dose
groups  and  with  a  previous  trial  in which  a dose  of  5  ×  107 PFU  MVA85A  had  been  administered.
Results:  There  were  no  serious  adverse  events  recorded  following  administration  of either  1  × 107 or
1  ×  108 PFU  of  MVA85A.  Systemic  adverse  events  were  more  frequently  reported  following  administra-
tion  of  1  ×  108 PFU  of  MVA85A  when  compared  to  either  5  ×  107 or 1  ×  107 PFU  of  MVA85A  but  were  mild
or  moderate  in  severity  and  resolved  completely  within  7 days  of  immunisation.  Antigen  speciﬁc  T cell
responses  as measured  by the IFN-  ELISPOT  were  signiﬁcantly  higher  following  immunisation  in  adults
receiving  1 × 108 PFU  compared  to  the  5  × 107 and  1  ×  107 doses.  Additionally,  a broader  range  of Ag85A
epitopes  are  detected  following  1 × 108 PFU  of  MVA85A.
Conclusion:  A  higher  dose  of  1 ×  108 PFU  of  MVA85A  is  well-tolerated,  increases  the  frequency  of  IFN-
secreting  T cells  detected  following  immunisation  and  broadens  the  range  of  Ag85A  epitopes  detected.
©  2012  Elsevier  Ltd.  
1. Introduction
TB remains one of the world’s most serious infectious diseases
and is responsible for more than 2 million deaths each year [1]. The
only available vaccine, Mycobacterium bovis Bacille Calmette Guérin
(BCG), confers some protection against disseminated TB in child-
hood but is largely ineffective at protecting against adult pulmonary
disease [2]. Thus, a more effective TB vaccine is urgently needed.
New vaccines for TB are assessed on measures including safety,
the ability to confer protection against Mycobacterium tuberculo-
sis (MTB)  challenge in preclinical animal models, and the ability to
induce an antigen speciﬁc IFN- immune response. Although there
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is no immune correlate of protection for TB, impairment of IFN-
 and IL-12 signalling in humans is associated with susceptibility
to mycobacterial disease and the measurement of antigen speciﬁc
IFN- remains the primary immune outcome in Phase I testing of
new TB vaccine candidates [3].
We have previously reported that recombinant Modiﬁed Vac-
cinia virus Ankara (MVA) expressing antigen 85A from MTB
(MVA85A) is well-tolerated and enhances the frequency of antigen-
speciﬁc IFN- producing T cells in adults, children and infants
previously vaccinated with BCG [4–10]. We  have also shown that
antigen speciﬁc T cells induced by MVA85A are highly polyfunc-
tional, and can express IFN-, TNF-, IL-2, MIP1- and IL-17 [11,12].
However, to date we  have not performed any dose-ﬁnding studies
in UK adults. We  therefore conducted a dose ﬁnding study in UK
adults to further understand the relationship between dose and
immunogenicity.
In South African infants the magnitude of the immune response
to MVA85A was  lower than previously reported for adults from
the same population and was  not increased by administration of
a higher dose [4]. In the present study we have compared the
magnitude and breadth of the T cell response induced by 1 × 107,
0264-410X © 2012 Elsevier Ltd. 
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Fig. 1.
5 × 107 and 1 × 108 plaque forming units (PFU) of MVA85A and have
shown that both are greater at 12 months following immunisation
in adults receiving a high dose of 1 × 108 PFU of MVA85A.
2. Methods
2.1. Ethics statement
Participants were recruited under a protocol approved by the
Oxfordshire Research Ethics Committee (OxREC A), ClinicalTri-
als.gov ID NCT00465465. Written informed consent was  obtained
from all individuals prior to enrolment in the trial.
2.2. Study design and participants
This  was a non-randomised, open-label, Phase I safety and
immunogenicity dose-ﬁnding study in healthy, previously BCG-
vaccinated adults (Fig. 1). Participants were negative for HIV, HBV
and HCV and aged 18–50 with no evidence of latent MTB infection,
as determined by IFN- ELISPOT response to ESAT-6 and CFP-10.
Volunteers  were vaccinated with a single immunisation of
MVA85A, administered intradermally over the deltoid region of the
arm. The ﬁrst 12 participants enrolled received the higher dose,
1 ×108 PFU of MVA85A and the following 12 participants received
1 × 107 PFU of MVA85A.
2.3. Follow up and safety measures
Safety was assessed by monitoring blood parameters using rou-
tine haematology and biochemistry assays at weeks 1 and 12
following immunisation. In addition, a diary card was completed
by all volunteers recording temperature and local and systemic
adverse events for 7 days following immunisation. Participants
returned for safety and immunological follow-up at 2 days, and 1, 2,
4, 8, 12, 24 and 52 weeks following immunisation. Adverse events
(AE) were graded as absent, mild, moderate or severe. A moder-
ate AE was deﬁned as having some impact on daily activity with
no or minimal medical intervention or therapy required whereas a
severe AE was deﬁned as an AE which restricted daily activity, with
medical intervention or therapy required.
2.4. Immunological assays
As with previous trials of MVA85A, the primary assay used to
measure immunogenicity was the ex vivo IFN- ELISPOT assay
used as previously described [9]. Antigen speciﬁc responses were
assessed by culturing PBMC (0.3 × 106) overnight for 18 h with
20 g/ml puriﬁed protein derivative (PPD), 10 g/ml recombinant
Ag85A protein or pools of Ag85A peptides (10 g/ml each peptide)
overlapping by 10 amino acids (Table 1). Blood samples for IFN-
ELISPOT were collected on the day of immunisation and 1, 2, 4, 8,
12, 24 and 52 weeks following immunisation. A
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Table 1
Sequences of Ag85A peptides used in the IFN- ELISPOT assay.
Sequence-15 mer  overlapping by 10 Number Sequence-15 mer overlapping by 10 Number
MQLVDRVRGAVTGMS 1 VGLSMAASSALTLAI 34
RVRGAVTGMSRRLVV 2 AASSALTLAIYHPQQ 35
VTGMSRRLVVGAVGA 3 LTLAIYHPQQFVYAG 36
RRLVVGAVGAALVSG 4 YHPQQFVYAGAMSGL 37
GAVGAALVSGLVGAV 5 FVYAGAMSGLLDPSQ 38
ALVSGLVGAVGGTAT 6 AMSGLLDPSQAMGPT 39
LVGAVGGTATAGAFS 7 LDPSQAMGPTLIGLA 40
GGTATAGAFSRPGLP 8 AMGPTLIGLAMGDAG 41
AGAFSRPGLPVEYLQ 9 LIGLAMGDAGGYKAS 42
RPGLPVEYLQVPSPS 10 MGDAGGYKASDMWGP 43
VEYLQVPSPSMGRDI 11 GYKASDMWGPKEDPA 44
VPSPSMGRDIKVQFQ 12 DMWGPKEDPAWQRND 45
MGRDIKVQFQSGGAN 13 KEDPAWQRNDPLLNV 46
KVQFQSGGANSPALY 14 WQRNDPLLNVGKLIA 47
SGGANSPALYLLDGL 15 PLLNVGKLIANNTRV 48
SPALYLLDGLRAQDD 16 GKLIANNTRVWVYCG 49
LLDGLRAQDDFSGWD 17 NNTRVWVYCGNGKPS 50
RAQDDFSGWDINTPA 18 WVYCGNGKPSDLGGN 51
FSGWDINTPAFEWYD 19 NGKPSDLGGNNLPAK 52
INTPAFEWYDQSGLS 20 DLGGNNLPAKFLEGF 53
FEWYDQSGLSVVMPV 21 NLPAKFLEGFVRTSN 54
QSGLSVVMPVGGQSS 22 FLEGFVRTSNIKFQD 55
VVMPVGGQSSFYSDW 23 VRTSNIKFQDAYNAG 56
GGQSSFYSDWYQPAC 24 IKFQDAYNAGGGHNG 57
FYSDWYQPACGKAGC 25 AYNAGGGHNGVFDFP 58
YQPACGKAGCQTYKW 26 GGHNGVFDFPDSGTH 59
GKAGCQTYKWETFLT 27 VFDFPDSGTHSWEYW 60
QTYKWETFLTSELPG 28 DSGTHSWEYWGAQLN 61
ETFLTSELPGWLQAN 29 SWEYWGAQLNAMKPD 62
SELPGWLQANRHVKP 30 GAQLNAMKPDLQRAL 63
WLQANRHVKPTGSAV 31 AMKPDLQRALGATPN 64
RHVKPTGSAVVGLSM 32 LQRALGATPNAVPAP 65
TGSAVVGLSMAASSA 33 GATPNAVPAPQGA 66
2.5. Data analysis
Data  was analysed using Stata software (StataCorp). As immune
data was available from multiple time-points, an area under the
curve (AUC) analysis was performed to obtain a value for overall
immune response to MVA85A. Kruskal–Wallis and Mann–Whitney
tests were used to determine signiﬁcant differences in immuno-
genicity between doses. Wilcoxon signed rank was used to
determine differences within a dosing group. Data was compared
between the 2 doses evaluated in this trial and with a previously
published trial where a dose of 5 × 107 PFU of MVA85A had been
administered [9].
3. Results
3.1. Participants
There were 24 participants enrolled into the study, 12 received
1 × 107 PFU MVA85A and 12 received 1 × 108 PFU of MVA85A.
Demographic characteristics are summarised in Table 2. There
were an equal number of males (33%) in each dosing group which
was equivalent to previous trials with MVA85A [9] (Table 2). A
higher proportion of participants were either healthcare workers
or born outside of the UK when compared to previous studies with
MVA85A.
Table 2
Demograpahic characteristics of UK adults vaccinated with MVA85A.
MVA85A dose
1 × 108 PFU n = 12 1 × 107 PFU n = 12 5 × 107 PFU n = 17–31
Male, no (%) 4 (33) 4 (33) 12 (39)
Median age, years (range) 25 (19–32) 27 (21–42) 27 (21–54)
Continent of birth, no (%)
UK  5 (42) 8 (67) 27 (87)
Africa 3 (25) 3 (25) 1 (3)
Other 4 (33) 1 (8) 3 (10)
Healthcare worker, no (%) 6 (50) 7 (67) 5 (16)
Interval between BCG and MVA85A, no
0–5 years 3 0 5
6–10 years 2 5 3
11–15 years 3 2 0
16–20 years 0 0 0
>20 years 4 5 9
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Table  3
Adverse events reported following immunisation with different doses of MVA85A.
Vaccine dose
1 × 108 PFU Subjects, n (%) 1 × 107 PFU Subjects, n (%) 5 × 107 PFU Subjects, n (%)
Local AE
Erythema 12 (100%) 12 (100) 31 (100%)
Pain 12 (100%) 6 (50%) 27 (87%)
Pruritus 8 (67%) 6  (50%) 18  (58%)
Scaling 3 (25%) 6 (50%) 29 (94%)
Swelling 12 (100%) 12 (100%) 31 (100%)
Systemic AE
Arthralgia 7 (58%) 1 (8%) 6 (19%)
Documented fever 5  (42%) 0 3  (10%)
Felt feverish 9 (75%) 2  (17%) 8  (26%)
Headache 10 (83%) 1 (8%) 11 (35%)
Lymphadenopathy 2 (17%) 0 4 (13%)
Malaise 7 (58%) 2 (17%) 12 (39%)
Myalgia 9 (75%) 0 11 (35%)
Nausea or vomiting 4 (33%) 1 (8%) 5 (16%)
Diarrhoea 1 (8%) 0 2 (6%)
Vasovagal syncope 0 0 1 (3%)
3.2. Safety of MVA85A
The  proﬁles of reported local AEs were similar across the two
doses tested, except for a lower frequency of pain recorded for the
1 × 107 PFU group (Table 3). Local AEs were either mild or mod-
erate with the exception of one report of severe swelling in the
1 × 107 PFU group and one report of severe pain in the 1 × 108 PFU
group  (Fig. 2A and B). The local AE proﬁle was comparable to
that previously reported for a dose of 5 × 107 PFU of MVA85A [9]
(Table 3). Systemic AEs were more frequently reported by partic-
ipants receiving the 1 × 108 PFU dose of MVA85A when compared
to the 1 × 107 and 5 × 107 PFU groups. However all systemic AEs
were recorded as either mild or moderate in severity (Fig. 2C and
D).
Fig. 2. Severity of adverse events induced by immunisation with different doses of MVA85A. Severity of the most frequently reported local adverse events following
immunisation with (A) 1 × 107 or (B) 1 × 108 PFU of MVA85A. Severity of the most frequently reported systemic adverse events following immunisation with (C) 1 × 107 or
(D) 1 ×108 PFU of MVA85A. White: mild, grey: moderate and black: severe.
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3.3. Effect of MVA85A dose on magnitude and longevity of T cell
response
Using  an ex vivo IFN- ELISPOT assay there was a signiﬁ-
cant increase in the number of Ag85A peptide, Ag85A protein
and PPD antigen speciﬁc T cells detected 7 days following immu-
nisation with either 1 × 107 (p < 0.0005–p < 05) or 1 × 108 PFU
(p < 0.0005–p < 05) of MVA85A when compared with baseline (pre-
vaccination) responses (Fig. 3(A)–(F)). Speciﬁc T cell frequencies
remained detectable and signiﬁcantly above those measured at
baseline for both doses in response to stimulation with 85 A pep-
tides and Ag85A protein at 52 weeks (Fig. 3(A)–(D). In the lower
dose group (1 × 107 PFU of MVA85A) PPD speciﬁc T cells were not
signiﬁcantly above baseline at 52 weeks but in the higher dose
group PPD responses were still signiﬁcantly higher than at baseline
(Fig. 3E and F).
3.4.  T cell epitope display in response to immunisation with
MVA85A
To  determine the breadth of epitope response to Ag85A, PBMC
collected 7 days following immunisation with MVA85A were stim-
ulated with 66 15mer Ag85A peptides overlapping by 10 amino
acids (P1–P66). T cell responses were measured using an ex
vivo IFN- ELISPOT assay. Immunisation with either 1 × 107 or
1 × 108 PFU of MVA85A induced a broad epitope response with pep-
tides P27 (GKAGCQTYKWETFLT), P28 (QTYKWETFLTSELPG) and
P38 (FVYAGAMSGLLDPSQ) being the most frequently detected epi-
topes (Fig. 4A). The total number of epitopes detected per volunteer
was higher in volunteers receiving 1 × 108 compared to 1 × 107 PFU
of MVA85A, (p < 0.05; Fig. 4B). Magnetic bead depletion using anti-
CD4 and anti CD8 Dynabeads conﬁrmed that all IFN- ELISPOT
responses were mediated by CD4+ T cells (data not shown).
3.5.  T cell responses are increased in response to high dose
MVA85A when compared to lower doses
A comparison was made between the number of antigen spe-
ciﬁc T cells detected using an IFN- ELISPOT assay from volunteers
receiving 1 × 107 and 1 × 108 (low and high doses) with previ-
ously published data from healthy, previously BCG vaccinated
adults receiving 5 × 107 PFU (mid dose) MVA85A [9,10]. High dose
MVA85A induced a signiﬁcantly greater response to Ag85A pep-
tide at 1 week following immunisation when compared to low
and mid  doses of MVA85A (p < 0.002 and p < 0.0003; Table 4). At
52 weeks high dose MVA85A induced a greater response than low
dose but not mid  dose MVA85A (p < 0.002; Table 4). The total anti-
gen speciﬁc T cell response induced by MVA85A was  assessed for
each dose by calculating the area under the curve (AUC) from 0 to
24 and 0–52 weeks following immunisation with MVA85A. High
dose MVA85A (1 × 108 PFU) induced a signiﬁcantly greater T cell
response than either mid  or low dose MVA85A over both 0–24
and 0–52 weeks following immunisation (Table 5). Finally, we  cal-
culated the T cell response to MVA85A relative to the screening
response. Using this analysis the dose of vaccine given did not have
any signiﬁcant effect on the peak immune response at 1 week fol-
lowing immunisation (Fig. 5). There was however a dose effect at
52 weeks following immunisation with a greater relative response
observed in adults receiving the highest dose.
4. Discussion
We  have previously reported that in BCG-vaccinated UK adults,
immunisation with 5 × 107 PFU of MVA85A was well-tolerated and
induced a strong T cell response that was maintained until at least
24 weeks following immunisation [10,13]. The optimal vaccine Ta
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Fig. 3. T cell responses in adults vaccinated with either 1 × 107 or 1 × 108 PFU of MVA85A. Antigen speciﬁc T cells were detected in PBMC from healthy, previously BCG
vaccinated adults receiving either 1 × 107 (panels A, C and E) or 1 × 108 (panels B, D and F) PFU of MVA85A. T cells were detected using an overnight ex vivo IFN- ELISPOT
assay with summed peptide pool (A and B), Ag85A protein (C and D) or PPD (E and F). Wilcoxon matched-pairs signed rank when compared to baseline (screening visit):
***p < 0005, **p < 005, *p < 05.
dose, both for safety and immunogenicity, needs to be determined
for the further development of MVA85A. Here, we report the results
of a dose ﬁnding study where we immunised BCG-vaccinated UK
adults with either 1 × 107 or 1 × 108 PFU of MVA85A. Both doses
were well-tolerated and induced a signiﬁcant increase in the fre-
quency of Ag85A speciﬁc T cells detected at peak (one week)
and up to one year following immunisation with MVA85A. When
comparing the 2 doses of MVA85A used in this trial with pre-
viously published data using an intermediate dose, a clear dose
response relationship was observed with a greater frequency of
T cells induced both at one and 52 weeks following immunisation
in volunteers receiving the higher, 1 × 108 PFU dose. When T cell
responses were examined relative to pre-immunisation responses
there  was no signiﬁcant effect of dose on the magnitude of response
induced at one week following immunisation, however, at one
year volunteers who received 1 × 108 PFU of MVA85A had higher
numbers of antigen speciﬁc T cells detected in peripheral blood.
There were no serious vaccine related AEs reported for any volun-
teer in either the 1 × 107 or 1 × 108 PFU of MVA85A dosing groups.
Published studies from other candidate TB vaccines currently in
clinical development include Aeras 402 [14], MTB72 [15,16] and
H1 [17]. Clinical studies were performed in different populations
and IFN- was  measured using different laboratory assays so direct
comparison of the immunogenicity of these vaccine candidates is
not possible. Both Aeras 402 and MVA85A have been evaluated
using a whole blood ICS assay and in BCG vaccinated adults the
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Fig. 4. T cell epitope display in adults vaccinated with either 1 × 107 or 1 × 108 PFU of MVA85A. A total of 66, 15-mer peptides overlapping by 10 amino acids (P1–P66) were
used to map  T cell responses to MVA85A. A) Open bars indicate individual peptide responses to 1 × 107 (n = 12) and black bars 1 × 108 PFU (n = 12) of MVA85A. B) The overall
number of peptides detected in response to MVA85A is signiﬁcantly higher in volunteers vaccinated with 1 × 108 (black circles) compared to 1 × 107 (white circles) PFU of
MVA85A. Responses detected using an ex vivo IFN- ELISPOT assay, Mann–Whitney *p < 0.05.
median total number of cytokine producing CD4 and CD8 cells in
response to Ag85A/B following Aeras 402 was approximately 0.2%
of CD4 and 0.3% of CD8 T cells and to the 1 × 108 dose of MVA85A
was 0.6% of CD4 and 0.2% of CD8 T cells [14,18]. Using a PBMC
ICS assay, both MVA85A and MTB72F induce approximately 800
CD3 + CD4 + CD40L + IFN- cells per 106 CD4+ T cells [15,18]. Using
a short-term cultured IFN- ELISPOT assay which incorporates an
overnight expansion of T cells, Van Dissel et al. reported a response
of approximately 500 SFU per million sustained to 32 weeks post
immunisation [17]. In a direct comparison conducted by four differ-
ent laboratories the short-term cultured IFN- ELISPOT was found
to amplify the IFN- response 4–10 fold when compared with the
18 h IFN- ELISPOT [19]. The IFN- response induced by the 1 × 108
dose of MVA85A is therefore higher at weeks 1–4 and at least equiv-
alent at weeks 24 and 52 to the week 32 responses reported for H1
[17,19]. The IFN- immune response induced by MVA85A is similar
to or greater than that induced by other candidate TB vaccines cur-
rently in clinical development, however, IFN- alone may  not be
a correlate of immune protection from disease. MVA85A has now
been evaluated in several different populations including those in
the UK, Gambia, South Africa and Senegal [4,5,7–10]. Our studies
have shown that the AE proﬁle for MVA85A is highly comparable
across different populations tested regardless of dose, BCG immu-
nisation status, MTB infection status, HIV status, age of participant
or country of residence. The frequency of mild or moderate sys-
temic AEs was  higher in UK volunteers receiving the 1 × 108 PFU
MVA85A dose when compared to the lower doses. Although we
have not tested doses higher than 1 × 108 PFU of MVA85A in clinical
trials, others have reported an increase in the frequency of severe
systemic AEs in adults receiving 5 × 108 PFU of a recombinant MVA
construct [16]. An MVA  expressing the inﬂuenza virus antigens NP
and M1  evaluated in UK adults induced severe systemic AEs includ-
ing nausea/vomiting, malaise or rigours in 5 of 8 volunteers tested
[16].
In South African infants a dose ﬁnding study with MVA85A
found no difference in the magnitude of T cell response induced
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Fig. 5. Dose related differences in T cell response to MVA85A. The fold increase in the
frequency of antigen speciﬁc T cells detected following immunisation with different
doses of MVA85A at the peak of response (1 week) and long term (52 weeks) over
the screening pre-immunisation responses were calculated for each dose. There was
a signiﬁcant difference in the fold increase between the high and low dose groups
at  52 weeks, but no signiﬁcant difference between high, mid or low doses at 1 week
post immunisation.
by 2.5 ×107, 5 ×107 or 1 ×108 PFU of MVA85A up to 6 months
following immunisation [4]. In contrast, in UK adults, in the data
presented here, we  observe a clear dose response relationship with
the greatest difference in response observed at 12 months follow-
ing immunisation. As the magnitude of IFN- response induced by
even the lowest dose of MVA85A is, at the peak of response at 7 days,
near the upper detection limit of the IFN- ELISPOT assay it is pos-
sible that this assay, at this time point, is not optimal for elucidating
differences between doses. We  have previously reported a signif-
icant effect of MVA85A dose on the induction of IL-17 responses
following immunisation with MVA85A in humans [11,20]. IL-17
producing cells were detected at a lower frequency than IFN-
producing cells and only detected in response to a high dose of
1 × 108 PFU MVA85A. As with IFN-, there was no dose-related
difference  observed in IL-17 responses in infants vaccinated with
MVA85A [4]. The lack of dose response in South African infants
when compared to UK adults could be due to differences in the
maturity of the immune system in adults and infants, differences in
environmental exposure or differences in study design as responses
were measured up to only 6 months in South African infants,
whereas the greatest effect of dose was observed at 12 months in
adults.
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